- 280,000 square-foot, state-of-the-art R&D hub
- Opened in 2014, the facility brings together approximately 1,000 Pfizer employees who were previously spread out across three area locations
- Located in the heart of Kendall Square, the unified Cambridge presence represents the opportunity to interlace Pfizer’s R&D capability with the densest biomedical community in the world
- Pfizer Cambridge researchers are focused on translating scientific knowledge into potential medical breakthroughs across areas of unmet need such as lupus, inflammatory bowel disease, kidney disease, type 2 diabetes, muscular dystrophy and Parkinson's disease
- The site’s new laboratory facilities, located at 610 and 700 Main Street, are leased from the Massachusetts Institute of Technology (MIT), continuing Pfizer’s tradition of working with MIT and other leading academic institutions to advance science, research and education
Functions: Pharmaceutical and Biotherapeutic/Biologics Research, Drug Metabolism, Biotechnology Units, Development and Medical, Support Functions.
Primary Therapeutic Areas: Inflammation and Remodeling, Immunoscience, Rare Diseases, Cardiovascular and Metabolic Diseases, and Neuroscience.
Key Technologies: Biological Technologies (Large Molecule Technologies), Synthetic & Medicinal Chemistry, Genetics & Mathematical Modeling, ADME (absorption, distribution, metabolism, excretion and toxicity), Computational Sciences.
In addition to the Pfizer’s Cambridge facilities, Massachusetts is home to Pfizer’s research and manufacturing site in Andover and is also the global headquarters for Pfizer’s Center for Therapeutic Innovation (CTI), which has established locations in New York City, San Diego and San Francisco. CTI is an entrepreneurial network of collaborations with leading academic medical centers.